Restylane Celebrates 25 Years

The hyaluronic acid-based filler line, launched in 1996, is celebrating 25 years and a growing portfolio of soft tissue fillers.

4 Restylane Lyft Box
ME2111_Newsmakers_FCX

This September, Galderma celebrated the 25th anniversary of Restylane. The hyaluronic acid (HA)-based filler was launched in Europe in 1996 and then became the first HA filler approved by the U.S. Food and Drug Administration (FDA) in 2003. Today, the Restylane line has expanded to include a total of 13 dermal filler products and boasts more than 50 million treatments worldwide.

This year alone, Restylane received two new FDA approvals. In February, the FDA approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21. In June, Galderma added a new product to the portfolio, Restylane Contour, which was approved for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21.

The company’s newest filler, Restylane Eyelight, launched in September in France, Germany, the Nordics, Portugal, Spain, and Switzerland, as a targeted treatment solution to combat under-eye shadows.

The non-animal stabilized hyaluronic acid (NASHA) fillers use XpresHAn technology (globally referred to as the OBT technology [Optimal Balance Technology]), to provide better tissue integration for more natural-looking results.

The Restylane portfolio offers a range of HA gels targeted toward specific indications including: Restylane L, Restylane Refyne, Restylane Defyne and Restylane Lyft with Lidocaine to smooth facial wrinkles and folds, such as smile lines; Restylane Defyne to augment and correct mild to moderate chin retrusion; Restylane Silk, Restylane-L and Restylane Kysse for lip augmentation; Restylane Lyft with Lidocaine to add lift and volume to the cheeks and back of the hands; and Restylane Contour to augment cheeks and correct midface contour deficiencies.

“The depth of experience from Restylane over the last 25 years has enabled us to build upon our expertise to innovate and develop new formulations and treatments,” said Flemming Ørnskov, MD, MPH, CEO of Galderma. “With over 30 ongoing pipeline projects in aesthetics alone, we will continue to enhance our diverse and broad portfolio of sophisticated brands to advance dermatology for every skin story.”

Inga Hansen is the managing editor of MedEsthetics.


More in News